LabCorp v. Metabolite, Inc., 548 U.S. 124 (2006), is the first case since Diamond v. Chakrabarty in which the U.S. Supreme Court indicated a renewed interest in examining the limits of patentable subject matter for advances in life sciences.
The U.S. Supreme Court's decision in LabCorp v. Metabolite, Inc., 548 U.S. 124 (2006), marked the first time since Diamond v. Chakrabarty that it expressed renewed interest in evaluating the scope of patentable subject matter for life science innovations.